LakeShore Biopharma Co. (LSB) - Net earnings per share (EPS TTM)

Brandmark of YS Biopharma (LSB)

Automated plants in China with autonomous power supplies served as the foundation for LakeShore Biopharma (LSB) growth. The current annual net income per unit confirms this resilience, while the value of 0.00 captures the metric level. Stable cash flow ensures leadership in the anti-rabies drug segment, while the aggressive commercialization of new vaccines based on proprietary adjuvants expands the company's production capacities.

LSB (ysbiopharm.com) Net earnings per share for the last 12 months history from 05/29/2024 to 10/04/2025

Metric breakdowns and analytics for LakeShore Biopharma Co., Ltd. (LSB)

- stock price and consensus target price:
Stock Price LakeShore Biopharma Co.|LSB - Forecast Levels Chart
- market capitalization indicators:
Market Capitalization LakeShore Biopharma Co., Ltd.|LSB - Total Enterprise Value
- business book valuation details:
Book Value per Share LakeShore Biopharma|LSB - Company Net Assets|Market Cap to Net Assets Ratio ysbiopharm.com|LSB - Aggregate Business Assets
- debt and liquidity details:
Total Debt to Capital LakeShore Biopharma Co.|LSB - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity YS Biopharma|LSB - Company Cumulative Debt|Debt to Book Capitalization Ratio LakeShore Biopharma Co., Ltd.|LSB - Company Long-Term Indebtedness|Company Short-Term Debt LakeShore Biopharma|Quick Liquidity ysbiopharm.com
- net income and valuation multiples indicators:
LSB - Company Net Income|Projected Future Earnings LakeShore Biopharma Co.|LSB - P/E Multiple|Future Price to Earnings LakeShore Biopharma|LSB - PEG Multiple|EV/EBITDA Multiple LakeShore Biopharma Co., Ltd.|LSB - Profit before interest, taxes and amortization|Earnings per share for the last twelve months LakeShore Biopharma|LSB - Net earnings per share for the last four quarters|Quarterly EPS earnings growth ysbiopharm.com|LSB - Earnings per share increase in current year|Net earnings per share growth forecast for next year LakeShore Biopharma Co.
- revenue and sales details:
LSB - Company Total Revenue|Company Projected Revenue LakeShore Biopharma Co.|LSB - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple LakeShore Biopharma Co., Ltd.
Basic company analysis:LSB - LakeShore Biopharma Co.
Manufactured products of YS Biopharma

The indicator is calculated by dividing the total annual net income by the total number of outstanding securities. This metric determines the actual earnings per share, which is critical when assessing business valuation. For LakeShore Biopharma Co. (LSB), such data reflects the efficiency of patent capitalization and compliance with GMP standards. High barriers to entry in the vaccine sector make this income more stable. By analyzing the trailing twelve-month earnings per share, an investor can identify the capital accumulation phase prior to a trend reversal.

Direct competitors

Summit Therapeutics - Net earnings per share (EPS TTM)|Earnings per one share for the last 12 months MRNA|PCVX: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Tarsus Pharmaceuticals Inc (TARS)|CRMD (CorMedix Corp) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Seres Therapeutics, Inc (MCRB)|Net earnings per share for the last 12 months SPRO (Spero Therapeutics)|Earnings per share for the last four quarters SCYX|Net earnings per share (EPS TTM) ANTX (AN2 Therapeutics)|Net earnings per share for the last four quarters PolyPid Ltd (PYPD)|ITRM - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months BiomX Inc.|soligenix.com (SNGX) - Earnings per share for the last twelve months|Earnings per share for the last 12 months SXTP|Earnings per share for the last twelve months Oragenics|OpGen Inc (OPGN) - Net earnings per share for the last four quarters